Objective: Percutaneous mechanical thrombectomy (PMT) is regularly used in the treatment of both venous and arterial thrombosis. Although there has been no formal report, PMT has been linked to cases of reversible postoperative acute kidney injury (AKI). The purpose of this study is to evaluate the risk of renal dysfunction in patients undergoing PMT vs catheter-directed thrombolysis (CDT) for treatment of an acute thrombus.
Arterial and venous thrombosis causes a significant disease burden for Americans with an estimated 275,000 cases of venous thrombosis per year in the United States and 30-day mortality rate approaching 12%. 1, 2 Acute limb ischemia attributable to arterial occlusion has poor outcomes with operative mortality ranging from 10% to 25% and limb salvage rates of 65%-79% with conventional techniques. [3] [4] [5] Endovascular techniques including percutaneous mechanical thrombectomy (PMT) and catheter-directed thrombolysis (CDT) are effective means of treatment of both venous and arterial thrombosis. [6] [7] [8] PMT with or without CDT for arterial thrombosis provides up to 96% angiographic success with improved limb salvage rates of 88.4% at 1 month and 9.3% 1-month mortality for arterial thrombosis. 8 For venous thrombosis, CDT significantly improves long-term incidence of post-thrombotic syndrome and addition of PMT decreases the cost and length of stay related to this disease process without changing outcomes. 7, 9 In recognition of this, the American College of Chest Physicians has included percutaneous therapies in their guidelines for treatment of proximal deep vein thrombosis (DVT). 10 The observation of acute kidney injury (AKI) after PMT, especially those involving higher aspiration volumes, led From the Department of Physiology and Biophysics, Case Western Reserve University a to this study. Hemolysis and hemoglobinuria resulting from the PMT procedure are thought to be the cause of this renal injury. 11 There are several reported cases in the literature, but these studies fail to fully characterize the incidence or severity of perioperative kidney injury in patients undergoing arterial or venous percutaneous thrombectomy. [11] [12] [13] [14] For this reason, we sought to further characterize and compare the incidence, severity, and time to recovery of AKI in patients undergoing CDT or PMT in our institution.
METHODS
This study is a retrospective review of all patients who underwent PMT or CDT for treatment of an arterial or venous thrombus at University Hospitals Case Medical Center and affiliated institutions from January 1, 2009 through December 31, 2014. The Institutional Review Board approved our protocol and allowed for a waiver of informed consent. Furthermore, because the study is a retrospective review of electronic medical records spanning many years, obtaining patient consent would likely not have been possible, and a waiver of consent posed minimal risk to patients. After Institutional Review Board approval, Current Procedural Terminology code query of Current Procedural Terminology codes 37184-37188 and 37211-37214 revealed 227 patients undergoing CDT or PMT during the specified time frame. Eightytwo were excluded due to existence of preoperative AKI (9), history of end-stage renal disease (ESRD) (14) , or lack of perioperative creatinine and glomerular filtration rate (GFR) values (59). The remaining 145 patients were grouped into one of the four following procedural categories: PMT only (n ¼ 15), PMT with tissue plasminogen activator (tPA) pulse-spray (n ¼ 42), PMT with CDT (n ¼ 70), and CDT only (n ¼ 18). If a patient had PMT, tPA pulse spray, and CDT, we included them in the PMT and CDT group. Procedural method was based on physician discretion and, thus, was related to prior practice and preference.
None of the patients were hemodynamically unstable, and there were no differences in approach to renal protective measures based on the procedural group.
Demographic data, perioperative data, and 6-month clinical outcomes were obtained from the hospital's electronic medical record system. Demographic variables included sex, age, race, body mass index, diabetes mellitus, hemoglobinA1C, congestive heart failure, coronary artery disease, coronary artery bypass graft, percutaneous coronary intervention, arrhythmias, hypertension, chronic obstructive pulmonary disease, DVT, cancer, chronic renal dysfunction, dialysis, and tobacco use. Perioperative variables included length of admission, type of thrombus (arterial or venous), anatomic location, duration of CDT, contrast volume, tPA volume, and PMT aspiration volume. Six-month clinical outcome variables included mortality, complications, readmissions for DVT or AKI, reoperations, primary patency, secondary patency, and limb salvage. Preoperative creatine kinase values were only available for a small portion of the patients in the study, and, thus, were not included.
Perioperative renal function was determined by assessing changes in creatinine and GFR laboratory values. Baseline, preoperative, and postoperative creatinine and GFR values were reviewed for each patient. Baseline was defined as the average value over the 6-month period before the intervention. Preoperative was defined as the most recent value before the intervention and was limited to <24 hours before the intervention. Maximum postoperative creatinine level was defined as the maximum value within 48 hours after the intervention. Minimum postoperative GFR level was defined as the minimum value within 48 hours after the intervention. We did not examine creatinine and GFR at 6 months postoperatively because these values could have been influenced by many other confounding variables, and our patients took no longer than 23 days to return to their baseline values.
The presence and severity of renal dysfunction were determined using the RIFLE (Risk, Injury, Failure, Loss, End-stage renal disease) criteria, which categorize the extent of renal dysfunction according to changes in creatinine and GFR values. 15 The RIFLE criteria categorize patients with renal dysfunction into one of the five following groups: risk (increase in creatinine by 50% or decrease in GFR by 25%), injury (increase in creatinine by 100% or decrease in GFR by 50%), failure (increase in creatinine by 200% or decrease in GFR by 75%), loss (complete loss of kidney function for at least 4 weeks), and ESRD (complete loss of kidney function for at least 3 months). 
RESULTS
Demographic data collected for all patients across the four procedural categories showed a mean age of 53.3 years and a sex distribution of 44% male patients. When stratified by procedural group, these data showed a statistically significant difference in age, history of coronary artery disease, hypertension, and chronic renal dysfunction (Table I) . When analyzing demographic variables among patients who developed renal dysfunction compared with those who did not, there was a statistically significant difference in race (P ¼ .013), diabetes mellitus (P ¼ .02), arrhythmias (P ¼ .007), hypertension (P ¼ .002), and history of malignancy (P ¼ .033; Table II) . One hundred forty-five patients underwent percutaneous intervention for arterial (53) and venous (92) thromboses. The average total contrast volume given was 114 6 66 mL, the average duration of CDT infusion was 28 6 14 hours, the average total tPA dose was 30 6 20 mg, and the average PMT aspiration volume was 175 6 92 mL. Thrombus location was the only significantly different variable between the AKI group and the no-AKI group (P ¼ .039; Table III ). The average contrast volume was statistically significant when stratified by procedural category (P < .01), but not when stratified by presence or absence of renal dysfunction.
The overall incidence of renal dysfunction, as defined by the RIFLE criteria, was 15% (22 out of 145 patients). The incidence of renal dysfunction was highest in the PMT/ tPA group at 21% (nine out of 42 patients), followed by the PMT group at 20% (three out of 15 patients) and the PMT/CDT group at 14% (10 out of 70 patients; Fig 1) . None of the 18 patients in the CDT only group experienced renal dysfunction. These differences in the incidence of renal dysfunction were statistically significant when comparing the PMT group to the CDT group (P ¼ .046), as well as when comparing the PMT/tPA pulse group to the CDT group (P ¼ .033). Eleven out of 53 patients (21%) with an arterial thrombus developed renal dysfunction, compared with 11 out of 92 patients (12%) of patients with a venous thrombus (Fig 2) .
The nine patients who had a pre-existing AKI were not included in the formal analysis in this study. However, we did examine preoperative and postoperative creatinine and GFR for these patients. Only one out of the nine patients had a postoperative worsening of values according to the RIFLE criteria; this patient had a pre-existing renal transplant with an occluded renal artery and underwent the CDT procedure. Among the 22 patients who developed renal dysfunction, the severity of renal dysfunction was determined according to the five categories within the RIFLE criteria (risk, injury, failure, loss, and ESRD), which assess the degree of perioperative changes in creatinine and GFR values. Among the 15 patients who underwent PMT only, two (13%) progressed to risk category and one (7%) progressed to injury category. Among the 42 patients who underwent PMT with tPA pulse spray, 5 (12%) progressed to risk category, 2 (5%) progressed to injury category, and 2 (5%) progressed to failure category. Among the 70 patients who underwent PMT and CDT, 6 (9%) progressed to risk category, 3 (4%) progressed to injury category, and 1 (1%) progressed to failure category. None of the 18 patients who underwent CDT only progressed to any of the categories of renal dysfunction. None of the patients in our study progressed to loss or ESRD, and no one progressed to dialysis within the same admission as the initial intervention. The average preoperative GFR for these 22 patients was 53.7 6 9.4 mL/min/1.73 m 2 . The minimum postoperative GFR within 48 hours was an average of 35 6 16 mL/min/1.73 m 2 .
Among patients who developed renal dysfunction, the average length of time for creatinine values to return to baseline values was 3.0 6 2.0 days in the PMT group, 6.6 6 6.9 days in the PMT/tPA pulse spray group, and 4.4 6 4.0 days in the PMT/CDT group (P ¼ .51). Across all procedural groups, the average length of time for creatinine values to return to baseline was 5.1 6 5.2 days. Even though PMT was associated with acute renal dysfunction compared with CDT, there was no difference in 6-month outcomes between these procedural groups. There was also no difference in 6-month outcomes when comparing patients who developed renal dysfunction to patients who did not (Table IV) . Variables that were assessed included mortality, reoperations, vessel patency, and limb salvage. When analyzing 6-month outcomes, one patient who was in the AKI group had malignancy and progressed to multisystem organ failure and dialysis. This was unrelated to the intervention for the thrombus.
DISCUSSION
PMT and CDT are both commonly used in the treatment of acute venous and arterial thrombosis. CDT has been shown to be an effective treatment for patients with acute DVT, both for achieving significant clot lysis and for decreasing the risk of post-thrombotic syndrome. [16] [17] [18] [19] However, CDT is associated with certain Re-thrombosis 11 (9) 3 (14) .49 Ischemia 7 (6) 1 (5) .82
Additional admission for DVT within 6 months 13 (11) (n ¼ 119) 4 (18) .33
Reoperations within 6 months (same limb or vessel) risks, particularly bleeding complications and is, thus, contraindicated in some patients. The combination of PMT and tPA pulse spray, also called pharmacomechanical thrombectomy, has been demonstrated to be both a safe and effective method of thrombus removal. [20] [21] [22] [23] Pharmacomechanical thrombectomy has also been shown to have similar functional success rates as CDT, while costing less and allowing for a shorter hospitalization period. 9 The combination of PMT and CDT has been demonstrated to be safe and effective for thrombosis removal. 24 PMT has been implicated in cases of postoperative renal dysfunction. Arslan et al 11 described a single case of a 16-year-old female with pulmonary embolism and DVT who was treated with PMT and CDT. The patient subsequently developed hemoglobinuria, her creatinine rose from 0.8 mg/dL preoperatively to 4.1 mg/dL 3 days later, and she was temporarily placed on peritoneal dialysis until her renal function returned to baseline 20 days after the procedure. Arslan et al 11 postulated that the PMT procedure caused hemolysis that led to the patient's acute renal dysfunction. Another case report from Dukkipati et al 12 described a 43-year-old female with bilateral pulmonary emboli who was treated with PMT only because of contraindications for thrombolytics. Postoperatively, the patient developed an AKI secondary to hemoglobinuria and was temporarily placed on dialysis, although her renal function recovered by postoperative day five. In addition to its effects on renal function, PMT has also been linked to cases of postoperative acute pancreatitis. 25, 26 Our data suggest a strong trend between PMT and postoperative renal dysfunction. Patients who underwent PMT showed a higher incidence of renal dysfunction compared with patients who underwent CDT. Although there was not a statistically significant difference when comparing all PMT groups with the CDT group (P ¼ .055), there was a statistically significant difference between the PMT only group and the CDT group (P ¼ .04), as well as between the PMT/tPA pulse group and the CDT group (P ¼ .03). CDT did not appear to be associated with renal dysfunction. These data support studies indicating an association between PMT and renal dysfunction. [11] [12] [13] [14] Although PMT was associated with higher incidence of acute renal dysfunction compared with CDT, there was no significant difference in long-term outcomes between these groups. Among the 22 patients who developed renal dysfunction, the average length of time until return to their baseline creatinine values was 5.1 6 5.2 days, with a maximum value of 23 days. None of these 22 patients progressed to dialysis within the same admission as the initial intervention. We did not check long-term GFR trends because other medical issues in these patients could have affected kidney function unrelated to the index procedures.
Our results confirm an observation of previous case studies that have demonstrated that PMT can result in postoperative acute renal dysfunction. 11, 12 The mechanism linking PMT to postoperative renal dysfunction appears to involve hemolysis and hemoglobinuria caused by the mechanical thrombectomy. 11 Contrastinduced nephrotoxicity could exacerbate this effect, but the difference in contrast volume between the AKI group and the no-AKI group in our study was not statistically significant. We also did not see a statistically significant difference in PMT aspiration volume in these groups, which may be due to the incomplete aspiration volume data. The effects of PMT on renal function should be considered when deciding between treatment methods for an acute thrombus. Although PMT has been shown to be an effective method of clot lysis that decreases lytic dosage and shortens procedure duration compared with CDT, it comes with the expense of intravascular hemolysis that could compromise renal function and, thus, should likely be avoided in patients with pre-existing renal dysfunction. Alternatives to PMT should also be explored. These data have influenced our practice because we are now more hesitant to use PMT because of potential renal complications. A limitation of our study was that it was a retrospective observational analysis with a small sample size and incomplete data, particularly regarding contrast volume and PMT aspiration volume. The interventions were not randomized and subject to systemic bias. Given these small numbers, multivariate analysis was not conducted. Future directions for this project include determining safe aspiration volumes and contrast volumes for patients undergoing PMT. In the meantime, limiting PMT duration and aspiration volumes, using renal protective measures including hydration, and maintaining postoperative vigilance is warranted.
CONCLUSIONS
This study demonstrates that there is an increased risk of postoperative renal dysfunction in patients undergoing PMT for treatment of acute vascular thrombosis compared with patients undergoing CDT. Potential renal complications should be considered when deciding between PMT and CDT for treatment of an acute arterial or venous thrombus. Patients who undergo PMT may benefit from perioperative vigilance and renal protective measures to decrease the likelihood of renal dysfunction secondary to PMT. 
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